Gonorrhea Ceftriaxone Dosage
For uncomplicated urogenital gonorrhea in adults, administer ceftriaxone 500 mg intramuscularly as a single dose, based on the most recent 2020 CDC guidelines. 1
Adult Dosing
The recommended dose has evolved based on antimicrobial resistance patterns:
- Current recommendation (2020-present): Ceftriaxone 500 mg IM single dose 1
- Previous recommendation (2012-2020): Ceftriaxone 250 mg IM single dose 2
The increase from 250 mg to 500 mg reflects antimicrobial stewardship principles and provides a greater margin of safety against emerging resistance, even though ceftriaxone MICs have remained stable in the United States with <0.1% showing elevated values 3. The FDA label confirms 250 mg IM as the approved dose for uncomplicated gonococcal infections 4, but clinical guidelines now recommend the higher 500 mg dose.
Route of Administration
Intramuscular injection is the required route - ceftriaxone should be injected deep into a large muscle mass with aspiration to avoid intravascular injection 4. The 500 mg dose provides sustained bactericidal blood levels that are highly effective at all anatomic sites of infection.
Anatomic Site Considerations
The 500 mg IM dose is effective for:
- Urogenital infections (cervix, urethra)
- Anorectal infections
- Pharyngeal infections 1
Pharyngeal gonorrhea requires particular attention as it is more difficult to eradicate than urogenital infections. The 500 mg dose is more effective than the previous 250 mg dose for pharyngeal infections 5. Research suggests that even 1 g may be needed for ceftriaxone-resistant pharyngeal strains 6.
Pediatric Dosing
For children with uncomplicated gonorrhea:
- Standard dose: 50 mg/kg IM single dose (maximum 250 mg) 4
- For acute bacterial otitis media: 50 mg/kg IM single dose (not to exceed 1 gram) 4
Combination Therapy Considerations
Chlamydia Cotreatment
If chlamydial coinfection has not been excluded, add doxycycline 100 mg orally twice daily for 7 days 1. This represents a shift from the 2012 guidelines that recommended routine dual therapy with azithromycin 1 g 2.
Key change in approach: The 2020 guidelines moved away from routine azithromycin combination therapy due to:
- Rising azithromycin resistance (nearly 5% of isolates with elevated MICs by 2018) 3
- Antimicrobial stewardship concerns about unnecessary azithromycin exposure 1
- Stable ceftriaxone susceptibility patterns in the United States 3
Azithromycin should now be reserved for documented chlamydial coinfection rather than given empirically.
Alternative Regimens
When Ceftriaxone is Unavailable
If ceftriaxone cannot be obtained:
- Cefixime 400 mg orally single dose PLUS azithromycin 1 g orally PLUS test-of-cure in 1 week 2
Important caveat: Cefixime provides lower and less sustained bactericidal levels than ceftriaxone and has limited efficacy for pharyngeal gonorrhea 2.
Severe Cephalosporin Allergy
There are no recommended alternative therapies for pharyngeal gonorrhea in patients with cephalosporin allergies 3. For urogenital/anorectal infections:
- Azithromycin 2 g orally single dose PLUS test-of-cure in 1 week 2
However, the risk of cephalosporin cross-reactivity in penicillin-allergic patients is often overestimated 7, and ceftriaxone may be used cautiously in many cases.
Critical Management Points
Test-of-Cure Requirements
Test-of-cure is not routinely required for patients treated with recommended ceftriaxone regimens 8. However, it is mandatory when:
- Alternative regimens are used 2
- Treatment failure is suspected
- Patient has severe cephalosporin allergy and receives alternative therapy 2
Perform test-of-cure 1 week after treatment using culture or NAAT 2.
Treatment Failure Protocol
If treatment failure occurs with the recommended regimen:
- Culture specimens and perform antimicrobial susceptibility testing 2
- Consult infectious disease specialist 2
- Report to CDC through local/state health department within 24 hours 2
- Ensure sex partners from preceding 60 days are evaluated and treated 2
Special Populations
Pregnancy: Pregnant women should receive the same ceftriaxone regimen as non-pregnant adults. Quinolones and tetracyclines are contraindicated 8.
HIV infection: Patients with HIV should receive identical treatment regimens as HIV-negative patients 8.
Neonates: Ceftriaxone is contraindicated in neonates ≤28 days receiving calcium-containing IV solutions due to precipitation risk 4. When used, IV doses should be given over 60 minutes to reduce bilirubin encephalopathy risk 4.
Emerging Resistance Considerations
While ceftriaxone remains highly effective in the United States, international treatment failures have been reported 3. Research suggests that 1 g IM ceftriaxone may be needed for ceftriaxone-resistant strains, particularly for pharyngeal infections 6. However, this is not yet incorporated into U.S. guidelines as resistance remains rare domestically.
The current 500 mg dose provides a safety margin while novel antimicrobials (zoliflodacin, gepotidacin) complete clinical trials 9, 10.